WO1998006431A3 - Method for treating diabetes - Google Patents

Method for treating diabetes Download PDF

Info

Publication number
WO1998006431A3
WO1998006431A3 PCT/US1997/014448 US9714448W WO9806431A3 WO 1998006431 A3 WO1998006431 A3 WO 1998006431A3 US 9714448 W US9714448 W US 9714448W WO 9806431 A3 WO9806431 A3 WO 9806431A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating diabetes
diabetes
compositions
methods
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/014448
Other languages
French (fr)
Other versions
WO1998006431A2 (en
Inventor
Kurt B Osther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP97938359A priority Critical patent/EP0859633A2/en
Priority to AU40708/97A priority patent/AU4070897A/en
Publication of WO1998006431A2 publication Critical patent/WO1998006431A2/en
Publication of WO1998006431A3 publication Critical patent/WO1998006431A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The instant invention provides for methods and compositions for the effective treatment of type I diabetes directed towards intervention of interferon alpha activity.
PCT/US1997/014448 1996-08-16 1997-08-15 Method for treating diabetes Ceased WO1998006431A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97938359A EP0859633A2 (en) 1996-08-16 1997-08-15 Method for treating diabetes
AU40708/97A AU4070897A (en) 1996-08-16 1997-08-15 Method for treating diabetes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69892696A 1996-08-16 1996-08-16
US08/698,926 1996-08-16
US76029996A 1996-12-04 1996-12-04
US08/760,299 1996-12-04

Publications (2)

Publication Number Publication Date
WO1998006431A2 WO1998006431A2 (en) 1998-02-19
WO1998006431A3 true WO1998006431A3 (en) 1998-06-18

Family

ID=27106305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014448 Ceased WO1998006431A2 (en) 1996-08-16 1997-08-15 Method for treating diabetes

Country Status (3)

Country Link
EP (1) EP0859633A2 (en)
AU (1) AU4070897A (en)
WO (1) WO1998006431A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582445B2 (en) 2001-02-22 2009-09-01 Genentech, Inc. Anti-interferon-α antibodies
US8080638B2 (en) 2005-02-10 2011-12-20 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
ES2549903T3 (en) 2008-05-07 2015-11-03 Argos Therapeutics, Inc. Humanized antibodies against human interferon alfa
US20140242038A1 (en) * 2011-10-11 2014-08-28 The Trustees Of Columbia University In The City Of New York Method for generating beta cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034307A2 (en) * 1980-02-16 1981-08-26 Hoechst Aktiengesellschaft Method for the production of human leucozyte interferon
WO1993004699A1 (en) * 1991-08-30 1993-03-18 Genentech, Inc. Therapeutic method for iddm
EP0588177A2 (en) * 1992-09-03 1994-03-23 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. An interferon-alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034307A2 (en) * 1980-02-16 1981-08-26 Hoechst Aktiengesellschaft Method for the production of human leucozyte interferon
WO1993004699A1 (en) * 1991-08-30 1993-03-18 Genentech, Inc. Therapeutic method for iddm
EP0588177A2 (en) * 1992-09-03 1994-03-23 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. An interferon-alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEWART ET AL.: "Induction of Type I Diabetes by Interferon-alpha in transgenic mice", SCIENCE, vol. 260, 25 June 1993 (1993-06-25), pages 1942 - 1946, XP002050198 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582445B2 (en) 2001-02-22 2009-09-01 Genentech, Inc. Anti-interferon-α antibodies
US8080638B2 (en) 2005-02-10 2011-12-20 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use

Also Published As

Publication number Publication date
EP0859633A2 (en) 1998-08-26
AU4070897A (en) 1998-03-06
WO1998006431A2 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
EP0717592A4 (en) Method and composition for the treatment of apathy-amotivation syndrome
ZA972929B (en) Systems for the treatment of commingled wastes and methods for treating commingled wastes.
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
AU5729098A (en) Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
ZA977513B (en) Skin tanning compositions and method.
HU9802721D0 (en) Method and composition for the treatment and prevention of hyperuricemia
ZA991053B (en) Method and composition for treatment of inflammatory conditions.
AUPM761094A0 (en) Treatment of hides
AU2825295A (en) Method for the treatment, prevention or minimization of hair loss
ZA986363B (en) Novel method of treatment.
ZA985237B (en) Novel method of treatment.
ZA986364B (en) Novel method of treatment.
ZA965346B (en) Methods of treating neuropeptide Y-associated conditions.
ZA974421B (en) Method of improving skin condition.
ZA986365B (en) Novel method of treatment.
ZA978257B (en) Method of treatment of amyotrophic lateral sclerosis.
ZA977867B (en) Method of treatment.
PL328925A1 (en) Method of treating bipolar disorders
GB9625398D0 (en) Method of treatment,manufacture,compositions and compounds
AU5265596A (en) Composition and method for the treatment of premenstrual syndrome
ZA200007396B (en) Method of treatment.
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers
AU7078298A (en) Method for the diagnosis, treatment and prophylaxis of premature ejaculation andcatheter for the diagnosis, treatment and prophylaxis of premature ejaculation
ZA977611B (en) Method and composition for treating substrates for wettability.
AUPM421894A0 (en) Method and composition for the prevention and/or treatment of ulcers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

WWE Wipo information: entry into national phase

Ref document number: 1997938359

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1997938359

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98510086

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997938359

Country of ref document: EP